ArticleJournal of bioenergetics and biomembranes2026
Oridonin ameliorates the ferroptosis of chondrocyte to play a chondroprotective role in osteoarthritis.
Article in Journal of bioenergetics and biomembranes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chondrocyte dysfunction is a pivotal event in the progression of osteoarthritis (OA). In recent years, ferroptosis has been identified as a key mechanism contributing to chondrocyte functional loss. Given the therapeutic potential of natural compounds derived from Traditional Chinese Medicine for OA, this study aims to investigate whether Oridonin (Ori) exerts a protective effect on osteoarthritic chondrocytes by inhibiting the ferroptosis pathway. Results indicated that Ori inhibited the ferroptosis-related features of chondrocyte via dosage-dependent manner. Mechanistically, acyl-CoA synthetase 4 (ACSL4) was found to be the target of Ori. More findings demonstrated that Ori was capable of suppressing ACSL4, thereby inhibiting ferroptosis in chondrocytes. In conclusion, Ori protected chondrocytes through ACSL4-mediated ferroptosis, which provided a theoretical foundation and a potential therapeutic target for OA.
Indexed as
Identifiers
41996075What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.